Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05678621
Registration number
NCT05678621
Ethics application status
Date submitted
11/02/2022
Date registered
10/01/2023
Titles & IDs
Public title
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
Query!
Scientific title
A Randomised Controlled Trial of Continuing Immunoglobulin Therapy, or Stopping With or Without Prophylactic Antibiotics, on Infection Rate in Patients With Acquired Hypogammaglobulinemia Secondary to Haematological Malignancies.
Query!
Secondary ID [1]
0
0
TRU-RLS-21
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RATIONALISE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Haematological Malignancy
0
0
Query!
Hypogammaglobulinemia
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - trimethoprim-sulfamethoxazole (co-trimoxazole)
Treatment: Drugs - amoxycillin/clavulanic acid and ciprofloxacin
Treatment: Drugs - Immunoglobulins
Experimental: ARM A: Stop immunoglobulin (Ig) and commence prophylactic oral antibiotics - Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. Nb: Doxycycline 100mg daily as an alternative for participants with hypersensitivity to co-trimoxazole.
Duration: 12 months. Route: PO
Experimental: ARM B: Stop immunoglobulin (without prophylactic antibiotics) - Participants will be prescribed amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg, to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical.
Nb: clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
Duration: 12 months. Route: PO
Active comparator: ARM C: Continue immunoglobulin - Participants will continue treatment with their current Ig replacement schedule. Participants will receive either Intravenous Ig (IVIg) or Subcutaneous Ig (SCIg)
* IVIg: Participants will be treated in accordance with the Criteria for Clinical Use of Immunoglobulin in Australia. Monthly (every 4 weeks ± 1 week) dose of 0.4g/kg, modified to achieve an Immunoglobulin G (IgG) trough level of at least lower limit of age-specific serum IgG reference range. In the first month of therapy, if IgG \<4g/L then an additional (loading) dose of 0.4g/kg may be given at the clinician's discretion.
* SCIg: Subcutaneous immunoglobulin weekly may be used in patients who meet local criteria for home based self-administration in centres with established SCIg programs. A loading IVIg dose may be given in the first month if required. Thereafter, dosing at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range.
Duration: 12 months.
Treatment: Drugs: trimethoprim-sulfamethoxazole (co-trimoxazole)
Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.
Treatment: Drugs: amoxycillin/clavulanic acid and ciprofloxacin
clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
Treatment: Drugs: Immunoglobulins
Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Event-free survival (EFS), defined as time from randomisation until occurrence of a Grade 3 or higher infection (as defined by CTCAE Version 5), or death from any cause.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
12 months following randomisation
Query!
Secondary outcome [1]
0
0
Proportion of patients who develop at least 1 Grade 3 or higher infection(s) from randomisation to 12 months.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
12 months following randomisation
Query!
Secondary outcome [2]
0
0
Proportion of patients with one or more clinically documented infections (symptoms/signs of infection requiring antimicrobial treatment) to 12 months.
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
12 months following randomisation
Query!
Secondary outcome [3]
0
0
Number of clinically documented infections (symptoms/signs of infection requiring antimicrobial treatment) to 12 months. Data collected from medical records will inform this outcome measure.
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
12 months following randomisation
Query!
Secondary outcome [4]
0
0
Proportion of patients with one or more microbiologically documented bacterial infections.
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
12 months following randomisation
Query!
Secondary outcome [5]
0
0
Number of microbiologically documented bacterial infections.
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
12 months following randomisation
Query!
Secondary outcome [6]
0
0
Time free from hospitalisation and antimicrobials with therapeutic intent.
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
12 months following randomisation
Query!
Secondary outcome [7]
0
0
Proportion of patients with one or more treatment-related adverse events
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
12 months following randomisation
Query!
Secondary outcome [8]
0
0
Number of treatment-related adverse events.
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
12 months following randomisation
Query!
Secondary outcome [9]
0
0
Proportion of patients with fluoroquinolone resistant organisms, co-trimoxazole resistant organisms, extended spectrum beta lactamases or multidrug resistant organisms isolated.
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
12 months following randomisation
Query!
Secondary outcome [10]
0
0
Number of infections with fluoroquinolone resistant organisms, co-trimoxazole resistant organisms, extended spectrum beta lactamases or multidrug resistant organisms isolated.
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
12 months following randomisation
Query!
Secondary outcome [11]
0
0
Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months
Query!
Assessment method [11]
0
0
QoL will be assessed using the EORTC QLQ-C30 questionnaire.
Query!
Timepoint [11]
0
0
Randomisation and 3, 6, 9 and 12 months following randomisation.
Query!
Secondary outcome [12]
0
0
Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months
Query!
Assessment method [12]
0
0
QoL will be assessed using the Functional Assessment of Cancer Therapy - Neutropenia (FACT-N) questionnaire.
Query!
Timepoint [12]
0
0
Randomisation and 3, 6, 9 and 12 months following randomisation.
Query!
Secondary outcome [13]
0
0
Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months
Query!
Assessment method [13]
0
0
QoL will be assessed using the EQ-5D-5L questionnaire.
Query!
Timepoint [13]
0
0
Randomisation and 3, 6, 9 and 12 months following randomisation.
Query!
Secondary outcome [14]
0
0
Costs associated with allocated treatment arm and infections during study
Query!
Assessment method [14]
0
0
Costs associated with each treatment arm with be aggregated into Australian dollars. Aggregate costs will be calculated based on the following data sources: medical records, infection-related hospitalisations (using unit costs based on unlinked data from the Victorian Admitted Episodes Dataset, Victorian Emergency Minimum Dataset and the Victorian Cost Data Collection), Medicare Benefits Scheme (MBS), Pharmaceutical Benefits Scheme (PBS) and Australian Immunisation Registry (AIR) data.
Query!
Timepoint [14]
0
0
12 months following randomisation
Query!
Secondary outcome [15]
0
0
Cost effectiveness of the allocated treatment arm
Query!
Assessment method [15]
0
0
Differences in costs and Quality Adjusted Life Years (QALYs) for each of the treatment arms will be aggregated into a cost effectiveness ratio. The following data sources will be used to calculate this outcome measure: the EORTC QLQ-C30 questionnaire will be used to calculate QALYS. Costs will be calculated based on the following data sources: medical records, infection-related hospitalisations (using unit costs based on unlinked data from the Victorian Admitted Episodes Dataset, Victorian Emergency Minimum Dataset and the Victorian Cost Data Collection), Medicare Benefits Scheme (MBS), Pharmaceutical Benefits Scheme (PBS) and Australian Immunisation Registry (AIR) data.
Query!
Timepoint [15]
0
0
12 months following randomisation
Query!
Secondary outcome [16]
0
0
Trough IgG level at 3, 6, 9 and 12 months from baseline.
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
3, 6, 9 and 12 months from baseline
Query!
Secondary outcome [17]
0
0
Proportion of patients in immunoglobulin cessation treatment arms who restart Ig over 12 months.
Query!
Assessment method [17]
0
0
Query!
Timepoint [17]
0
0
12 months following randomisation
Query!
Secondary outcome [18]
0
0
Covid anti-spike protein levels at baseline, 3, 6, 9, and 12 months.
Query!
Assessment method [18]
0
0
Query!
Timepoint [18]
0
0
3, 6, 9 and 12 months following baseline
Query!
Eligibility
Key inclusion criteria
1. Aged greater than or equal to 18 years of age
2. Diagnosis of chronic lymphocytic leukaemia (CLL), multiple myeloma (MM) or non-Hodgkin lymphoma (NHL).
3. Patients must be receiving Ig (IV or subcutaneous - SCIg) replacement for prevention of bacterial infections due to hypogammaglobulinaemia for longer than 6 consecutive months.
4. Patient is eligible for trial of Ig cessation in the opinion of the treating clinician and local investigator.
5. Life expectancy greater than 12 months.
6. Able to give informed consent, and willing and able to comply with each of the treatment arms.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Prior or planned allogeneic haematopoietic stem cell transplantation.
2. Major infection (Grade 3 or higher) in preceding 3 months, and/or current active infection requiring antimicrobial treatment.
3. Already receiving daily antibiotic prophylaxis for the purpose of preventing bacterial infection (Note: patients may receive antiviral, antifungal and Pneumocystis jirovecii pneumonia (PJP) prophylaxis).
4. Intolerance of all trial antibiotic options in either arm A or arm B.
5. Communication, compliance or logistical issues that are likely to limit patient's ability to take prophylactic or emergency antibiotics, or to obtain urgent medical attention for symptoms of infection.
6. Pregnant or breastfeeding.
7. Severe renal impairment (estimated or measured creatinine clearance of less than 30 mL/min).
8. Previous splenectomy.
9. Previous participation in this trial.
10. Treating team deems enrolment in the study is not in the best interests of the patient.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/11/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/04/2027
Query!
Actual
Query!
Sample size
Target
300
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,VIC
Query!
Recruitment hospital [1]
0
0
Canberra Hospital - Garran
Query!
Recruitment hospital [2]
0
0
Concord Hospital - Concord
Query!
Recruitment hospital [3]
0
0
Royal North Shore - St Leonards
Query!
Recruitment hospital [4]
0
0
Monash Medical Centre - Clayton
Query!
Recruitment hospital [5]
0
0
Austin Hospital - Heidelberg
Query!
Recruitment hospital [6]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment hospital [7]
0
0
Sunshine Hospital - St Albans
Query!
Recruitment postcode(s) [1]
0
0
2605 - Garran
Query!
Recruitment postcode(s) [2]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [3]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [4]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [5]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [6]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [7]
0
0
3021 - St Albans
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Monash University
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The aim of the study is to find out if patients with blood cancers receiving immunoglobulin (Ig) for the purpose of preventing infections can safety stop immunoglobulin after six months of therapy, and take oral antibiotics instead to prevent serious infections. Patients may be eligible to join this study if they are aged 18 years or above, have an acquired hypogammaglobulinaemia secondary to a haematological malignancy, and have been receiving intravenous or subcutaneous Ig for longer than 6 consecutive months. Participants will be randomised (allocated by chance) to one of three treatment groups, as follows: * Stop immunoglobulin (IVIg or SCIg) and be given oral antibiotics to take every day (ARM A) * Stop immunoglobulin (IVIg or SCIg) and be given oral antibiotics to keep at home to use as soon as symptoms of an infection develop (ARM B) * Continue receiving immunoglobulin (IVIg or SCIg) - this is the usual care group (ARM C) The duration of each treatment is for 12 months from study entry. Participants will be asked to attend a screening/baseline visit so that their treating clinician can assess their eligibility for the trial and collect baseline data. If eligible for the trial, participants will then be randomly allocated to one of the three treatment groups. Once randomised, active participation in the study will last for 13 months. During this period, participants will be asked to return to the hospital for a study visit every 3 months, with monthly telephone visits to check-in on your progress between each in-person visit. Participants will also be asked to complete a study diary, recording treatment compliance and signs/symptoms of infection experienced throughout the study period. Types of assessments and data collected will include: Medical history, demographics, physical examination, blood tests, stool sample, quality of life questionnaires, information about your general health, hospitalisations, medications and procedures. In order to assess and compare the cost-effectiveness of the treatment groups, the study team will also request authorisation from participants to access their Medicare Benefits Schedule (MBS), Pharmaceutical Benefits Scheme (PBS), and Australian Immunisation Register (AIR) data.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05678621
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Prof Erica Wood
Query!
Address
0
0
Monash University
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Prof Zoe McQuilten
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+61 3 9903 0379
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Individual participant data will not be publicly available. Data will only be presented as a whole, no individual data will be published or presented.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05678621